Expression of proliferating cell nuclear antigen (PCNA) in gastric carcinoma: no evidence for prognostic value.
It has been proposed that immunostaining with PC10, a monoclonal antibody against proliferating cell nuclear antigen (PCNA), is of prognostic value in gastric carcinoma. Gastric carcinomas from a series of 90 patients in whom survival data were known have been studied. There was no relation between the degree of PC10 immunostaining assessed semiquantitatively and survival.
Mangham
D C
DC
Department of Pathology, University of Birmingham.
Rowlands
D C
DC
Newbold
K M
KM
Reynolds
G M
GM
Fielding
J W
JW
Hallissey
M T
MT
D000230:Adenocarcinoma / Q000276:immunology* / Q000401:mortality; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000032:analysis*; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen; D013274:Stomach Neoplasms / Q000276:immunology* / Q000401:mortality
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; D018809:Proliferating Cell Nuclear Antigen